Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Editas Medicine Announces Third Quarter 2025 Results and Business Updates
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Editas Medicine to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.